Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.16M | -35.57M | -21.20M | -17.30M | -3.26M |
| Total Depreciation and Amortization | 552.00K | 550.00K | 731.00K | 585.00K | 1.12M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.67M | 22.39M | 1.51M | 1.41M | 3.20M |
| Change in Net Operating Assets | -4.60M | -6.66M | 4.30M | 12.30M | -21.77M |
| Cash from Operations | -22.54M | -19.29M | -14.67M | -3.01M | -20.71M |
| Capital Expenditure | -- | 0.00 | 0.00 | 0.00 | -237.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.82M | 26.66M | -8.00K | 4.00K | -18.26M |
| Cash from Investing | 15.82M | 26.66M | -8.00K | 4.00K | -18.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00K | -- | 9.36M | 153.00K | 57.71M |
| Repurchase of Common Stock | -2.00K | -7.65M | -1.00K | -43.00K | -196.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 7.70M | -7.70M | 0.00 | -- |
| Cash from Financing | 0.00 | 50.00K | 1.66M | 110.00K | 57.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.71M | 7.42M | -13.02M | -2.89M | 18.30M |